AstraZeneca Plc

(For other news from Reuters Health Summit, click on http://www.reuters.com/summit/Health13) May 6 (Reuters) - The U.N. World Health Organization and the U.S. Centers for Disease Control and Prevention are already working with samples of the new H7N9...

(For other news from Reuters Health Summit, click on http://www.reuters.com/summit/Health13) By Bill Berkrot NEW YORK, May 6 (Reuters) - Teva Pharmaceutical Industries Ltd has yet to make any serious inroads into China, but its chief executive...

* Head of diabetes says eyeing broadest portfolio in industry * Aiming to win bigger slice of growing market * Lilly currently No.4 in $40 bln diabetes market * Lilly says mainly addressing GPs, not specialists By Ludwig Burger and Frank Siebelt...

Por Ludwig Burger y Frank Siebelt FRANCFORT (Reuters) - Eli Lilly, el cuarto fabricante mundial de medicamentos para la diabetes, buscará tener la variedad más amplia posible de fármacos antidiabéticos con el fin de ganar una mayor porción de ese...

* Nanomedicine promises greater precision and monitoring * Pfizer, Amgen, AstraZeneca among firms placing bets * Early-stage research but scientists see momentum building By Ben Hirschler LONDON, May 3 (Reuters) - Is nanomedicine the next big thing? A...

By Olivia Oran April 30 (Reuters) - Life sciences-focused software company Veeva Systems is planning an initial public offering that could come in the third quarter and has selected banks to lead the deal, according to two people familiar with the...

The following are the top stories on the business pages of British newspapers. Reuters has not verified these stories and does not vouch for their accuracy. The Telegraph: GDP NUMBERS 'ENCOURAGING' BUT ROAD AHEAD IS NOT EASY - OSBORNE The better-than-...

* Rise in UK GDP lifts sterling, gilt yields * World shares gain for a 5th day on central bank hopes * Dollar under pressure from disappointing U.S. data * Gold, copper oil recover week's losses By Richard Hubbard LONDON, April 25 (Reuters) -...

LONDON, April 25 (Reuters) - AstraZeneca's sales fell by a bigger-than-expected 13 percent in the first quarter as patent expiries sent revenue from key medicines skidding lower, underscoring the turnaround challenge facing Britain's second biggest...

LONDRES, 25 abr (Reuters) - Las ventas de AstraZeneca disminuyeron más que lo previsto en un 13 por ciento en el primer trimestre debido a que el vencimiento de patentes cobró un precio muy alto, lo que subraya el desafío que enfrenta la segunda...

Reports: Initial jobless claims for week ended April 20, 7:30 a.m.; Mortgage rates for week ended April 25, 9 a.m.; Natural gas inventories for week ended April 20, 9:30 a.m.; Kansas City Fed manufacturing index for April, 10 a.m. Local earnings:...

LONDON, April 23 (Reuters) - Cash-rich drug companies are likely to make more acquisitions in 2013 after a thin year for deals in 2012, ratings agency Moody's Investors Service said on Tuesday. In an review of the global sector reiterating a "stable"...